ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0786

A Combination of Dimensionality Reduction Techniques Reveals Novel HLA-DR+ ‘Candidate’ Antigen-Presenting Cell Subsets (cAPC) in Patients with Rheumatoid Arthritis (RA)

Christian Geier1, Jon Giles1, Samantha Gaines2, Christopher Depender1, Joan Bathon1 and Robert Winchester1, 1Division of Rheumatology, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, 2Division of Rheumatology, Columbia University Vagelos College of Physicians and Surgeons, New York

Meeting: ACR Convergence 2020

Keywords: Bioinformatics, Cardiovascular, Dendritic cells, Monocytes/macrophages, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 7, 2020

Title: RA – Etiology & Pathogenesis Poster

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: The presentation of MHC-peptide complexes to T lymphocytes via antigen-presenting cells (APC) is a crucial step in the initiation of immune responses. Dendritic cells (DC) are potent APC with remarkable plasticity that are classically divided into DC1 (141+), DC2 (1c+) and plasmacytoid (pDC) subsets. Decreases in these classic blood DC occur in patients suffering from autoimmune conditions including RA. We have previously reported that in RA, peripheral decreases of DC2 are strongly associated with clinical RA features including measures of cardiovascular disease (CVD), the main driver of RA related mortality. We reasoned that — given the importance of DC in immune activation — their apparent decrease might be more adequately explained by phenotypic alteration rather than ‘true’ disappearance. We hypothesized that this highly plastic compartment under inflammatory conditions might harbor alternative phenotypes that lack classic combinations of DC markers while retaining potential APC function (HLA-DR).

Methods: Patients with RA and SLE — two prototypical autoimmune rheumatic diseases (ARD) — and healthy donors (HD) underwent immunophenotyping; to capture the presumed candidate APC we first gated all viable HLA-DR+ cells. By eliminating the lymphoid lineage (CD3–,CD19–) we created an HLA-DR+Lin– superset containing classic DCs, monocytes and candidate APC. We next classified HLA-DR+Lin– cells into established non-lymphoid APC [classic DC and Monocyte] by using a combination of t-distributed stochastic neighbor embedding (t-SNE) and manual annotation. HLA-DR+Lin– cells that did not meet established APC criteria we designate candidate APC. To screen for common characteristics across patients within this subset we performed Uniform Manifold Approximation and Projection (UMAP).

Results: Strikingly, candidate APC were higher in ARD (n=21) (7.3% vs. 3.9%; [median %DR+, Kruskall-Wallis tests), particularly SLE (11.8% vs 3.9%; p=0.01). UMAP of RA cAPC identified a dominant cluster of CD45RA+CD14lo as a feature present across RA samples. CD14intCCR2+ cAPC represented a second major cluster. Confirming traditional gating approaches, DC classical subsets were decreased in ARD when compared with HD (n=10): DC1 0.1% vs 0.4% (p=0.01), DC2 2.6% vs 5.3% (p=0.03) and pDC 1.5% vs 2.9% (p=0.03). Classical (CD14+CD16–) monocytes were not different (p=0.19) whereas intermediate monocytes (CD14+CD16+) were higher in RA than SLE and HD (13.2% vs. 8.9% vs. 6.2; p=0.01).

Conclusion: Using a combination of dimensionality reduction techniques on an unbiased HLA-DR+Lin– APC superset we observed the appearance of HLA-DR+ candidate APC. These cells do not conform to traditional APC gating definitions and were increased in ARDs relative to healthy controls. Their dominant cluster showed widespread expression of CD45RA suggesting, despite lack of CD1c expression, a developmental relationship with DC2. CD14/CCR2 co-expression was seen in three patients, supporting a relationship to monocyte-derived DC in these individuals. The novel subsets may be implicated in the pathophysiology of ARDs including RA associated cardiovascular disease, potentially via anomalous presentation of self-antigen to T lymphocytes.

Figure 1. Example of t-distributed Stochastic Neighbor Embedding (t-SNE) guided manual annotation of high-dimensional flow cytometry data of a healthy blood donor. Non-lymphoid cells with antigen-presenting potential (DR positive, Lin negative) can be classified into established lineages in 97.79%. Bottom row shows color coded overlays of expression intensity (red positive, blue negative) of select monocyte and DC markers (CD14, CD16, CD303, CD141). Dimensions not shown: CCR2, XCR1, CD1c, CD11c, CD45RA, CD56, CD163, CD123, CD172a (SRPα).

Figure 2. Example of t-SNE guided manual annotation of flow cytometry data of an active RA patient (CDAI 29), showing the emergence of 14.37% of phenotypes with antigen-presenting potential (HLA-DR positive) which are unclassifiable using standard definitions (candidate APC).

Figure 3. Uniform Manifold Approximation and Projection (UMAP) using 33157 candidate APC which were concatenated from 10 RA patients. A. Color coded by donor, showing three main clusters with cells derived from multiple donors. B. Same UMAP Heat-coded overlay showing expression of CD45RA in majority of the dominant cluster. Dimensions not shown: CD14, CD16, CD141, 303, CCR2, XCR1, CD1c, CD11c, CD45RA, CD56, CD163, CD123, CD172a (SRPα).


Disclosure: C. Geier, None; J. Giles, Gilead, 5, Eli Lilly, 5, Bristol Myers Squibb, 5, Pfizer, 2; S. Gaines, None; C. Depender, None; J. Bathon, None; R. Winchester, None.

To cite this abstract in AMA style:

Geier C, Giles J, Gaines S, Depender C, Bathon J, Winchester R. A Combination of Dimensionality Reduction Techniques Reveals Novel HLA-DR+ ‘Candidate’ Antigen-Presenting Cell Subsets (cAPC) in Patients with Rheumatoid Arthritis (RA) [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/a-combination-of-dimensionality-reduction-techniques-reveals-novel-hla-dr-candidate-antigen-presenting-cell-subsets-capc-in-patients-with-rheumatoid-arthritis-ra/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-combination-of-dimensionality-reduction-techniques-reveals-novel-hla-dr-candidate-antigen-presenting-cell-subsets-capc-in-patients-with-rheumatoid-arthritis-ra/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology